People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2016 |
| Genomedx Inc. | — | Other Health Care | Series B | $72.9M | $176.3M | 2020 |
| On-Q-ity, Inc. | — | Biotechnology | Seed | $2.5M | $111.0M | 2012 |
ROBERT S. EPSTEIN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT S. EPSTEIN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| CRAIG JOHNSON | 1 | 16 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Michael Liang | 1 | 9 |
| Carl Weissman | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Bryan E. Roberts | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| William Rastetter | 1 | 4 |
| Henry Skinner | 1 | 4 |
| John Mendlein | 1 | 4 |
| Frank Muhlenbeck | 1 | 4 |
| Andrew Levitch | 1 | 3 |
| TODD HOLMES | 1 | 3 |
| AMIR S. NASHAT | 1 | 3 |
| Tina S. Nova | 1 | 3 |
| Robert Hershberg | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.